Premium
Systems pharmacology guided platform development for the integrated Microphysiological Systems
Author(s) -
Yu Jiajie,
Cirit Murat,
Carrier Rebecca,
Chen Kelly,
Cilfone Nicholas,
Coppeta Jonathan,
Griffith Linda,
Hughes David,
Large Emma,
Lauffenburger Douglas,
Lever Amanda,
Mescher Mark,
PrantilBaun Rachelle,
Sarkar Ujjal,
Stokes Cynthia,
Tannenbaum Steven,
Wishnok John
Publication year - 2015
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.29.1_supplement.1027.1
Subject(s) - systems pharmacology , clinical pharmacology , drug development , computer science , preclinical research , preclinical testing , pharmacology , risk analysis (engineering) , drug , medicine , medical physics
The current drug clinical development is suffering a high attrition rate. More robust preclinical tools are needed to identify unpredicted toxicity and efficacy problems in the early stage of the drug development. Microphysiological Systems (MPS) program aims to develop in vitro interactome system to mimic physiological responses of drugs and provide more reliable preclinical results that is predictive of clinical outcomes. Systems pharmacology approach was used to analyze experimental data and guide integrated MPS platform development. Experimental results from MPSs were analyzed to obtain mechanism‐based information that could not be easily interpreted without systems pharmacology models. A series of data‐driven computational models for 1‐, 2‐, and 4‐MPSs was also developed to study platform operations under physiological conditions. Moreover, our systems pharmacology framework also assisted researchers to develop integrated MPS platform in physiological manner. Overall, systems pharmacology has been accepted as a very useful approach for quantitatively analyzing experimental results, experimental design and accelerating physiological Microphysiological Systems platform development.